COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine are available for routine office visits. More Information-PLEASE CLICK HERE

Clinical Trial: RTX-240-01

Trial Status: Open
Trial Type: Solid Tumors
Disease Type: Solid Tumors All
Trial ID RTX-240-01
Sponsor ID Rubius Therapeutics

PHASE 1/2 STUDY OF RTX-240 MONOTHERAPY Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors.

Locations

Fairfax Office

Learn More About This Trial
Other Relevant Trials
Trial ID 1336-0011
Sponsor ID

An open label phase Ib dose finding study of BI 836880 in combination with BI 754091 to characterize safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer and in other solid tumors

Trial ID 20344
Sponsor ID SGNTUC-019

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations